Peter Blume-Jensen is Chief Executive Officer, President and Director of Acrivon Therapeutics, Inc. (ACRV). The company reported total compensation of $2,718,538 for fiscal year 2025.
| Salary | $709,893 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $1,592,245 |
| Non-equity incentive plan | $410,400 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $6,000 |
| Total | $2,718,538 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Acrivon Therapeutics, Inc. filed April 30, 2026, accession 0001193125-26-194206.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Peter Blume-Jensen this page | Chief Executive Officer, President and Director | $2,718,538 |
| Kristina Masson | Executive Vice President, Business Operations, Director | $1,424,926 |
| Eric Devroe | Chief Operating Officer | $1,358,003 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Acrivon Therapeutics, Inc. compensation brief.
Peter Blume-Jensen's compensation sits inside Acrivon Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.